AstraZeneca's sone-ve extends overall survival in advanced stomach cancer trial
AstraZeneca's experimental antibody-drug conjugate sone-ve doubled survival time in patients with advanced stomach cancer who had received at least two prior treatments, exceeding analyst expectations in late-stage trial data.
